GlassScriptPhysician profile
Golnaz Parsa
NPI 1801175039
$2,927.31
in general payments reported to CMS, 2019-2025
18 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $415 · 2023: $956 · 2024: $625 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,237 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.25 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $670.46 | 2021-2025 | Nemluvio, Aklief |
| Incyte Corporation | $475.61 | 2021-2025 | Opzelura |
| Abbvie INC. | $430.58 | 2021-2025 | |
| Janssen Biotech, INC. | $321.17 | 2022-2025 | Tremfya, Simponi Aria, Stelara |
| Amgen INC. | $277.18 | 2021-2025 | Otezla |
| Lilly USA, LLC | $192.14 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $121.55 | 2023 | |
| Ucb, INC. | $85.57 | 2021-2025 | Bimzelx |
| Allergan, INC. | $70.00 | 2021-2022 | |
| Krystal Biotech INC | $48.47 | 2023 | Vyjuvek |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $48.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $45.93 | 2023 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.90 | 2023 | Spevigo, Cyltezo |
| Blueprint Medicines Corporation | $23.50 | 2023 | |
| Merz North America, INC. | $18.73 | 2023 | Xeomin |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Helsinn Therapeutics (U.S.), INC. | $18.54 | 2023 | Valchlor |
| Kyowa Kirin, INC. | $16.86 | 2023 | Poteligeo |
| Regeneron Healthcare Solutions, INC. | $16.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Golnaz Parsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.